Agenus (AGEN) Profit After Tax (2010 - 2026)
Agenus (AGEN) posted quarterly Profit After Tax of $39.2 million for Q1 2026, up 248.68% year-over-year from $11.2 million in Q1 2025, and up 469.45% quarter-over-quarter from -$10.6 million in Q4 2025.
Analysis
Agenus (AGEN) Profit After Tax (2010 - 2026) Analysis & Trends
Agenus' Profit After Tax history runs 17 years deep, the most recent figure standing at $39.2 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 248.68% year-over-year to $39.2 million; the TTM figure through Mar 2026 stood at $62.5 million (up 132.02% YoY), while the FY2025 annual figure was -$3.1 million, up 98.67% from the prior year.
- Profit After Tax for Q1 2026 stood at $39.2 million, up from -$10.6 million in the prior quarter.
- The five-year high for Profit After Tax was $63.9 million in Q3 2025, with the low at -$74.1 million in Q4 2022.
- The 5-year median for Profit After Tax is -$50.6 million (2022), against an average of -$40.2 million.
- The sharpest annual moves came in 2022 and 2026: Profit After Tax plunged 131.99% in 2022, then soared 248.68% in 2026.
- Agenus' Profit After Tax stood at -$74.1 million in 2022, then jumped by 34.44% to -$48.6 million in 2023, then rose by 3.66% to -$46.8 million in 2024, then jumped by 77.33% to -$10.6 million in 2025, then soared by 469.45% to $39.2 million in 2026.
- Business Quant data shows AGEN's Profit After Tax at $39.2 million in Q1 2026, -$10.6 million in Q4 2025, and $63.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Agenus | 340.21 Mn | 340.21 Mn | 34.52 Mn | -567,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -567,000.00 |
| Mar 31, 2026 | 39.21 Mn |
| Dec 31, 2025 | -10.61 Mn |
| Sep 30, 2025 | 63.91 Mn |
| Jun 30, 2025 | -30.01 Mn |
| Mar 31, 2025 | -26.37 Mn |
| Dec 31, 2024 | -46.81 Mn |
| Sep 30, 2024 | -67.21 Mn |
| Jun 30, 2024 | -54.80 Mn |
| Mar 31, 2024 | -63.45 Mn |
| Dec 31, 2023 | -48.58 Mn |
| Sep 30, 2023 | -64.53 Mn |
| Jun 30, 2023 | -73.43 Mn |
| Mar 31, 2023 | -70.89 Mn |
| Dec 31, 2022 | -74.10 Mn |
| Sep 30, 2022 | -56.72 Mn |
| Jun 30, 2022 | -49.24 Mn |
| Mar 31, 2022 | -50.60 Mn |
| Dec 31, 2021 | -67.61 Mn |
| Sep 30, 2021 | 177.28 Mn |